TARS — Tarsus Pharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00- $3.45bn
- $3.12bn
- $182.95m
- 61
- 17
- 81
- 53
Annual cashflow statement for Tarsus Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -26.8 | -13.8 | -62.1 | -136 | -116 |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | 4.12 | 15.9 | 13.7 | 17.2 | 27.5 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 1.46 | 1.37 | -0.951 | 0.306 | 3.84 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -21.1 | 3.75 | -49 | -117 | -83 |
| Capital Expenditures | -0.456 | -0.586 | -0.506 | -5.5 | -6.57 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | — | — | -144 | 146 | -193 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -0.456 | -0.586 | -145 | 141 | -199 |
| Financing Cash Flow Items | 91.7 | -0.303 | -0.95 | 0 | -35.4 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 132 | 0.021 | 94 | 130 | 155 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 110 | 3.18 | -99.7 | 153 | -128 |